Cholangiocarcinoma

Videos — July 10, 2025

Dr. Ghassan Abou-Alfa, a renowned medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the global impact of cholangiocarcinoma and the pivotal role of the CCA Summit in driving research, collaboration, and improved patient care.

Evolving Targeted Treatment Landscape in Biliary Tract Cancer

Cholangiocarcinoma

Web Exclusives — May 21, 2024

The podcast provides peer-to-peer physician perspectives on targeted treatments in BTC, focusing on fibroblast growth factor receptor (FGFR) inhibitors.

First-Line Treatment of Advanced Biliary Tract Cancers (BTCs)

Cholangiocarcinoma

Ask the Expert — April 10, 2024

Use of first-line (1L) IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin (gem-cis) chemotherapy in patients with locally advanced or metastatic biliary tract cancers

KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC

Cholangiocarcinoma

In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.

Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA

Cholangiocarcinoma

This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.

Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor

Cholangiocarcinoma

Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.

KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA

Cholangiocarcinoma

Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.

Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy

Cholangiocarcinoma

In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.

Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies

Cholangiocarcinoma

Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.

Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC

Cholangiocarcinoma

In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.

Cholangiocarcinoma

Subscribe Today!

I'd like to receive:

Stay In The Know

Cholangiocarcinoma

Page 1 of 14

Subscribe Today!

I'd like to receive:

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content